Risks of needle-stick injuries and non-occupational exposure, including local guidelines, and post-exposure prophylaxis and follow up

Overview

Needlestick and other sharps injuries (occupational) and non-occupational blood/body fluid exposures both require prompt risk assessment for bloodborne virus transmission (HIV, hepatitis B, hepatitis C) and, where indicated, post-exposure prophylaxis (PEP) initiated as soon as possible after exposure
A common occupational health presentation in healthcare settings; non-occupational exposures (sexual assault, shared injecting equipment, community sharps injuries) follow a parallel risk assessment and management framework

Transmission risk varies by virus and exposure type - percutaneous needlestick HIV transmission risk is low (approximately 0.3%) but non-zero, and is influenced by factors including needle gauge, depth of injury, visible blood on the device, and source patient viral load

Risk assessment considers source patient status (known/testable, or unknown), exposure type/severity, and timing since exposure - source testing (where the source patient consents and is identifiable) substantially refines the risk assessment and PEP decision
Baseline testing of the exposed individual (HIV, hepatitis B/C status) establishes a pre-exposure reference point for later interpretation of follow-up results

HIV PEP: per the 2025 US Public Health Service guidelines, the preferred regimen is a once-daily three-drug combination (an integrase inhibitor plus two NRTIs, e.g. bictegravir/tenofovir alafenamide/emtricitabine as a single tablet) for 28 days, started as soon as possible after exposure - efficacy diminishes with delay, and PEP should not be withheld while awaiting source patient testing if risk is significant
Hepatitis B: PEP depends on the exposed individual's vaccination/immunity status - immunoglobulin plus vaccination for non-immune individuals with a high-risk source
Hepatitis C: no PEP available - follow-up viral load/serology monitoring to detect and treat early infection if it occurs, given highly effective direct-acting antiviral treatment if transmission does occur

Source patient testing and consent considerations, PEP timing urgency (efficacy falls with delay), hepatitis B immune status-dependent PEP, follow-up testing schedule (typically extending to 3-6 months post-exposure depending on the virus)
HIV PEP should be started as soon as possible after a significant exposure and should not be delayed while awaiting source patient testing results if the exposure is assessed as high-risk - the regimen can be stopped early if source testing subsequently returns negative, but efficacy is time-dependent and delay is the more costly error

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.